249 related articles for article (PubMed ID: 32211937)
1. [Mistletoe in the treatment of cancer patients].
Rostock M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 May; 63(5):535-540. PubMed ID: 32211937
[TBL] [Abstract][Full Text] [Related]
2. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
Melzer J; Iten F; Hostanska K; Saller R
Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
[TBL] [Abstract][Full Text] [Related]
4. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?].
Bar-Sela G; Gershony A; Haim N
Harefuah; 2006 Jan; 145(1):42-6, 77. PubMed ID: 16450726
[TBL] [Abstract][Full Text] [Related]
5. Mistletoe in immunology and the clinic (short review).
Stein GM; Schietzel M; Büssing A
Anticancer Res; 1998; 18(5A):3247-9. PubMed ID: 9858890
[TBL] [Abstract][Full Text] [Related]
6. Patient' and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment.
Steigenberger C; Schnell-Inderst P; Flatscher-Thöni M; Plank LM; Siebert U
Eur J Oncol Nurs; 2023 Aug; 65():102338. PubMed ID: 37321128
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
8. Phytochemical profile and therapeutic potential of Viscum album L.
Nazaruk J; Orlikowski P
Nat Prod Res; 2016; 30(4):373-85. PubMed ID: 25813519
[TBL] [Abstract][Full Text] [Related]
9. [Immunostimulatory properties of mistletoe extracts and their application in oncology].
Wrotek S; Skawiński R; Kozak W
Postepy Hig Med Dosw (Online); 2014 Oct; 68():1216-24. PubMed ID: 25380204
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses.
Twardziok M; Meierhofer D; Börno S; Timmermann B; Jäger S; Boral S; Eggert A; Delebinski CI; Seifert G
BMC Complement Altern Med; 2017 Apr; 17(1):237. PubMed ID: 28454538
[TBL] [Abstract][Full Text] [Related]
12. [Vysorel/Isorel--cancer drug from Viscum album. Documentation No.20].
Kast A; Hauser SP
Schweiz Rundsch Med Prax; 1990 Mar; 79(11):332-4. PubMed ID: 2315589
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Cancer Biotherapy by Viscum Album Extract Isorel: Overview of Evidence Based Medicine Findings.
Sunjic SB; Gasparovic AC; Vukovic T; Weiss T; Weiss ES; Soldo I; Djakovic N; Zarkovic T; Zarkovic N
Coll Antropol; 2015 Sep; 39(3):701-8. PubMed ID: 26898069
[TBL] [Abstract][Full Text] [Related]
14. Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma.
Twardziok M; Kleinsimon S; Rolff J; Jäger S; Eggert A; Seifert G; Delebinski CI
PLoS One; 2016; 11(9):e0159749. PubMed ID: 27589063
[TBL] [Abstract][Full Text] [Related]
15. Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations.
Zuzak TJ; Rist L; Eggenschwiler J; Grotzer MA; Viviani A
Anticancer Res; 2006; 26(5A):3485-92. PubMed ID: 17094471
[TBL] [Abstract][Full Text] [Related]
16. Mistletoe in conventional oncological practice: exemplary cases.
Legnani W
Integr Cancer Ther; 2008 Sep; 7(3):162-71. PubMed ID: 18956494
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
Felenda JE; Turek C; Stintzing FC
J Ethnopharmacol; 2019 May; 236():100-107. PubMed ID: 30840914
[TBL] [Abstract][Full Text] [Related]
18. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
[TBL] [Abstract][Full Text] [Related]
19. Phytochemical analysis and in vitro anti-proliferative activity of Viscum album ethanolic extracts.
Holandino C; Melo MNO; Oliveira AP; Batista JVDC; Capella MAM; Garrett R; Grazi M; Ramm H; Torre CD; Schaller G; Urech K; Weissenstein U; Baumgartner S
BMC Complement Med Ther; 2020 Jul; 20(1):215. PubMed ID: 32646417
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of K562 Leukemia Cells to Doxorubicin by the Viscum album Extract.
Srdic-Rajic T; Tisma-Miletic N; Cavic M; Kanjer K; Savikin K; Galun D; Konic-Ristic A; Zoranovic T
Phytother Res; 2016 Mar; 30(3):485-95. PubMed ID: 26692465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
